Kirkland biotech company raises $196M for wearable defibrillator
Kestra Medical Technologies, a Kirkland-based biotechnology company specializing in wearable defibrillators, has raised $196 million in its latest funding round.
In a recent release, CEO Brian Webster stated, “This oversubscribed financing is validation of the excitement and confidence that new and existing investors have for Kestra. With this funding, our team is ready to aggressively compete.”
Founded in 2014, Kestra has developed a wearable defibrillator that monitors patients’ heart rhythms and delivers a life-saving shock if arrhythmia is detected. Kestra also has a companion app that collects heart data for patients and can send the data to healthcare professionals.